로레디플론
Lorediplon
기본 정보
- CAS
917393-39-6- 표준 SMILES
CC(=O)N(C)c1cc(-c2ccnc3c(C(=O)c4cccs4)cnn23)ccc1F- InChIKey
NQPOCLFSADOXBR-UHFFFAOYSA-N- 분자식
- C20H15FN4O2S
- 평균 분자량
- 394.4 g/mol
- 단동위원소 질량
- 394.08997494
개요
an hypnotic
이름 및 식별자
- 우선 이름
- Lorediplon
- IUPAC
- N-[2-fluoro-5-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-N-methylacetamide
- 현지명
- 로레디플론
- 영어명
- Lorediplon
- 분자식
- C20H15FN4O2S
- 분자량
- 394.42
이름 및 동의어
Lorediplon917393-39-6VKU6Z23NSYAcetamide, N-(2-fluoro-5-(3-(2-thienylcarbonyl)pyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-methyl-N-(2-Fluoro-5-(3-(thiophene-2-carbonyl)pyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-methylacetamideN-[2-fluoro-5-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-N-methylacetamideDTXSID00238684N-{2-fluoro-5-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl}-N-methylacetamideN-(2-fluoro-5-(3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl)phenyl)-N-methylacetamidelorediplonumRefChem:154102DTXCID50161175
이름 더 보기
로레디플론Lorediplon, 10 mM in DMSOThionorphine HydrochlorideAcetamide, N-[2-fluoro-5-[3-(2-thienylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-N-methyl-GABA Receptor,γ-Aminobutyric acid Receptor,inhibit,Inhibitor,Lorediplon,Gamma-aminobutyric acid Receptor
Lorediplon [INN]UNII-VKU6Z23NSYGF-015535-00Lorediplon?MFCD27987938LOREDIPLON [WHO-DD]orb1296263SCHEMBL1316601
데이터베이스 식별자
- CAS
917393-39-6- PubChem CID
- 12004146
- DTXSID
DTXSID00238684- ChEMBL
CHEMBL4303403- UNII
- VKU6Z23NSY
물성
구조 계산 물성
- XLogP
- 2.8
- 극성 표면적
- 95.8 Ų
- 수소 결합 공여자 수
- 0
- 수소 결합 수용자 수
- 6
- 회전 가능 결합 수
- 4
- 무거운 원자 수
- 28
- 형식 전하
- 0
- 복잡도
- 609
물리화학적 성질
- 저장 조건
- -20 °C · Store at -20°C
- 용해도
- 25 mg/ml; · DMF: 25 mg/ml; DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml; DMSO: 14 mg/ml
- 물리적 상태
- 결정성 고체
- 색상
- Light yellow to yellow
화학 및 산업
응용 분야
개요Lorediplon is a non-benzodiazepine belonging to pyrazolopyrimidine family isunderdevelopment for the management for insomnia. Lorediplon acts by modulationof the GABAgreceptor. Its long plasma half-life has the potential of hypnotic effect. Ithas the potential for maintenance of sleep and the sleep architecture. In the phase Ipharmacodynamic study,it showed better efficacy in quality and maintenance ofsleep as compared with zolpidem. It has been shown to be well tolerated, safe with noresidual effects as compared with other sedative-hypnotic. Currently, the drug has completed Phase ll clinical trial. Results indicated strongefficacy in sleep maintenance with an acceptable safety profile. It also seems topreserve natural sleep architecture.
용도Lorediplon is GABAA receptor modulator and is used in the treatment of insomnia.
관련 반응
2건
화합물 노트
불러오는 중…